BHCM
NKTR icon

Brevan Howard Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Brevan Howard Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.49M Buy
+48,474
New +$2.76M 0.03% 358
2025
Q4 		– Sell
-4,109
Closed -$234K – 2133
2025
Q3 		$234K Buy
+4,109
New +$136K ﹤0.01% 1685

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Brevan Howard Capital Management's NKTR Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 48,474 shares worth $3.49M. The stake represents 0.03% of the portfolio and ranks #358 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in NKTR as recently as Q3 2025.

Brevan Howard Capital Management first reported a position in NKTR in Q3 2025 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Brevan Howard Capital Management held 48,474 shares of Nektar Therapeutics worth $3.49M as of Q1 2026.
  • Nektar Therapeutics was a new Brevan Howard Capital Management position in Q1 2026.
  • Nektar Therapeutics made up 0.03% of Brevan Howard Capital Management's portfolio in Q1 2026, its #358 holding.
  • Brevan Howard Capital Management first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.